New oral drug for refractory herpes: FDA approves pritelivir for immunocompromised adults
When commonly used antiviral drugs fail to heal herpes lesions, immunocompromised patients often face prolonged treatment. The newly approved Hovilpri blocks viral replication through a different mechanism, and a randomized trial showed that it can increase the rate of complete lesion healing within 28 days. However, its approved scope of use and long-term benefits must still be clearly distinguished.